118 related articles for article (PubMed ID: 23207289)
1. The significance of Wilms Tumor Gene (WT1) and p53 expression in curettage specimens of patients with endometrial carcinomas.
Matalka I; Obeidat B; Mohtaseb A; Awamleh A
Pathol Res Pract; 2013 Jan; 209(1):19-23. PubMed ID: 23207289
[TBL] [Abstract][Full Text] [Related]
2. Wilms Tumor Gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray.
Dupont J; Wang X; Marshall DS; Leitao M; Hedvat CV; Hummer A; Thaler H; O'Reilly RJ; Soslow RA
Gynecol Oncol; 2004 Aug; 94(2):449-55. PubMed ID: 15297187
[TBL] [Abstract][Full Text] [Related]
3. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of WT1 protein in endometrial cancer.
Ohno S; Dohi S; Ohno Y; Kyo S; Sugiyama H; Suzuki N; Inoue M
Anticancer Res; 2009 May; 29(5):1691-5. PubMed ID: 19443388
[TBL] [Abstract][Full Text] [Related]
5. Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.
Obeidat BR; Matalka II; Mohtaseb AA; Al-Kaisi NS
Pathol Oncol Res; 2013 Apr; 19(2):229-35. PubMed ID: 23055021
[TBL] [Abstract][Full Text] [Related]
6. Correlation between WT1 expression and cell proliferation in endometrial cancer.
Dohi S; Ohno S; Ohno Y; Soma G; Kyo S; Inoue M
Anticancer Res; 2009 Nov; 29(11):4887-91. PubMed ID: 20032452
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
[TBL] [Abstract][Full Text] [Related]
8. A role of thymidine phosphorylase and P53 tissue protein expression in biology of endometrial cancer.
Mazurek A; Kuć P; Mazurek-Wadołkowska E; Laudański T
Neoplasma; 2008; 55(3):261-5. PubMed ID: 18348659
[TBL] [Abstract][Full Text] [Related]
9. Comparison of D&C and hysterectomy pathologic findings in endometrial cancer patients.
Wang X; Huang Z; Di W; Lin Q
Arch Gynecol Obstet; 2005 Jul; 272(2):136-41. PubMed ID: 15666177
[TBL] [Abstract][Full Text] [Related]
10. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
Bonfitto VL; de Angelo Andrade LA
Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
12. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
13. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
14. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.
Engelsen IB; Stefansson I; Akslen LA; Salvesen HB
Am J Obstet Gynecol; 2006 Oct; 195(4):979-86. PubMed ID: 16677592
[TBL] [Abstract][Full Text] [Related]
15. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
16. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
17. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
19. Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
Coosemans A; Moerman P; Verbist G; Maes W; Neven P; Vergote I; Van Gool SW; Amant F
Gynecol Oncol; 2008 Dec; 111(3):502-8. PubMed ID: 18929401
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 and p53 expression in stage I endometrial carcinoma.
Giatromanolaki A; Sivridis E; Koukourakis MI; Harris AL; Gatter KC
Anticancer Res; 1998; 18(5B):3689-93. PubMed ID: 9854478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]